← Back to Search

Monoclonal Antibodies

ALXN1850 for Hypophosphatasia

Phase 1
Waitlist Available
Research Sponsored by Alexion
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose through up to 168 hours postdose
Awards & highlights

Study Summary

This study is evaluating whether a drug called ALXN1850 is safe and well tolerated in people with HPP.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose through up to 168 hours postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose through up to 168 hours postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence Of Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events
Secondary outcome measures
Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single IV And Multiple SC Doses Of ALXN1850
Area Under The Plasma Concentration Versus Time Curve Within The Dosing Interval (AUCtau) Values Of The First SC Versus IV Administration
Assess incidence of Antidrug Antibody (ADA) and Neutralizing Antibody (NAbs)
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALXN1850Experimental Treatment1 Intervention
Three experimental cohorts will be administered 3 dosages (low, medium, high) of ALXN1850, respectively, via IV infusion and/or SC over multiple administration intervals.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALXN1850
2021
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

AlexionLead Sponsor
246 Previous Clinical Trials
39,247 Total Patients Enrolled
25 Trials studying Hypophosphatasia
1,597 Patients Enrolled for Hypophosphatasia
Alexion Pharmaceuticals, Inc.Lead Sponsor
252 Previous Clinical Trials
41,122 Total Patients Enrolled
25 Trials studying Hypophosphatasia
1,597 Patients Enrolled for Hypophosphatasia
Alexion PharmaceuticalsLead Sponsor
230 Previous Clinical Trials
37,393 Total Patients Enrolled
21 Trials studying Hypophosphatasia
1,405 Patients Enrolled for Hypophosphatasia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of ALXN1850 in Participants With Hypophosphatasia (HPP)
2021. "Study of ALXN1850 in Participants With Hypophosphatasia (HPP)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04980248.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top